| By Agilent Technologies |
| Monday, 11 August 2008 |
 |
Agilent Technologies (NYSE: A) today announced the availability of Agilent SampliQ SPE, a solid phase extraction (SPE) product line for fast and cost-effective purification of extracts
|
|
that improves the accuracy and reproducibility of analytical results. Agilent's SampliQ SPE product line replaces and expands upon the previous AccuBONDII SPE product line. A new line of polymer SPE products complement the silica and other sorbents such as carbon and Florisil PR. Formats ranging from the most popular cartridge sizes to 96-well plates are available to meet every solid phase extraction requirement.
"More and more of our customers
want an end-to-end workflow |
|
|
solution, and look to Agilent to help them achieve the very highest
quality result at every step of their analysis," said Ron Majors, senior scientist at Agilent. "The new SampliQ product line is one way we are responding to our customers' needs while reflecting our commitment to serving the solid phase extraction market."
All Agilent SampliQ SPE products are manufactured under stringent quality-control standards in Agilent's Delaware manufacturing facilities. Industry-leading quality-control processes ensure consistent chemical composition, controlled particle size and lot-to-lot sorbent uniformity for superior flow-through and performance.
Solid phase extraction is a cornerstone technique in the analytical workflow of complex samples because it reduces the |
|
number and amount of potential interferences that can jeopardize a separation, detection and quantification.
Researchers in the food safety, pharmaceutical, environmental, and forensic industries use solid phase extractions. The growing importance of food safety, particularly in regions such as Asia-Pacific, presents a growing need for effective solid phase extraction to help with food safety analyses.
_____________________________
Want to read more?
_____________________________
Hovine buys drug manufacturing plant in China
Leading the way in respect of quality standards for pharmaceutical excipients
Sun Pharma Comments on Taro’s Potential Sale of its Irish Operations |
|
|
